FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891418171> ?p ?o ?g. }

• W2891418171 endingPage "3012" @default.
• W2891418171 startingPage "3012" @default.
• W2891418171 abstract "3012 Background: The immunosuppressive enzyme indoleamine 2, 3-dioxygenase 1 (IDO1) facilitates immune tolerance in cancer via T-cell suppression, and IDO1 overexpression is associated with poor survival. Epacadostat, an oral inhibitor of IDO1, has been shown to be well tolerated as monotherapy and in combination with checkpoint inhibitors. ECHO-202/KEYNOTE-037 is a phase 1/2 study evaluating the safety and efficacy of oral epacadostat plus IV pembrolizumab in patients (pts) with advanced tumors. Based on phase 1 outcomes, epacadostat 100 mg BID plus pembrolizumab 200 mg Q3W was selected for phase 2 evaluation. This analysis summarizes phase 2 safety experience in the overall population of ECHO-202/KEYNOTE-037 (pooled across tumor types) at an October 29, 2016 data cutoff. Methods: Phase 2 pts were ≥18 years of age with advanced or recurrent melanoma (MEL), non–small cell lung cancer (NSCLC), renal cell carcinoma (RCC), urothelial carcinoma (UC), triple-negative breast cancer, squamous cell carcinoma of head and neck (SCCHN), ovarian cancer, diffuse large B-cell lymphoma, or microsatellite instability–high colorectal cancer. Results: The overall safety population comprised 244 pts receiving ≥1 study treatment dose. Median age was 63 years, 52% were women, and 91% were white. As of data cutoff, 134 study pts (55%) discontinued study treatment, primarily due to disease progression (n = 97). Median exposure to study treatment was 86 days (range, 1–374 days). TRAEs occurring in ≥5% of pts were fatigue (23%); rash (16%); diarrhea and nausea (7% each); increased alanine aminotransferase, increased aspartate aminotransferase, and pruritus (6% each); and pyrexia (5%). A total of 37 pts (15%) had grade ≥3 TRAEs; the most common grade ≥3 TRAEs were increased lipase (asymptomatic) and rash (3% each). TRAEs led to discontinuation in 3% of pts. Conclusions: Epacadostat 100 mg BID plus pembrolizumab 200 mg Q3W was associated with an acceptable safety profile in pts with advanced cancers, supporting continued evaluation of the combination. The phase 3 ECHO-301/KEYNOTE-252 MEL study is ongoing and additional phase 3 studies (NSCLC, UC, RCC, SCCHN) are planned. Clinical trial information: NCT02178722." @default.
• W2891418171 created "2018-09-27" @default.
• W2891418171 creator A5001562050 @default.
• W2891418171 creator A5004935250 @default.
• W2891418171 creator A5019741373 @default.
• W2891418171 creator A5020955148 @default.
• W2891418171 creator A5028592995 @default.
• W2891418171 creator A5031721461 @default.
• W2891418171 creator A5037195922 @default.
• W2891418171 creator A5042503296 @default.
• W2891418171 creator A5043561754 @default.
• W2891418171 creator A5044613951 @default.
• W2891418171 creator A5052730435 @default.
• W2891418171 creator A5070005513 @default.
• W2891418171 creator A5070734531 @default.
• W2891418171 creator A5075799959 @default.
• W2891418171 creator A5076736008 @default.
• W2891418171 creator A5085317448 @default.
• W2891418171 date "2017-05-20" @default.
• W2891418171 modified "2023-09-30" @default.
• W2891418171 title "Safety of epacadostat 100 mg bid plus pembrolizumab 200 mg Q3W in advanced solid tumors: Phase 2 data from ECHO-202/KEYNOTE-037." @default.
• W2891418171 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.3012" @default.
• W2891418171 hasPublicationYear "2017" @default.
• W2891418171 type Work @default.
• W2891418171 sameAs 2891418171 @default.
• W2891418171 citedByCount "26" @default.
• W2891418171 countsByYear W28914181712017 @default.
• W2891418171 countsByYear W28914181712018 @default.
• W2891418171 countsByYear W28914181712019 @default.
• W2891418171 countsByYear W28914181712020 @default.
• W2891418171 countsByYear W28914181712021 @default.
• W2891418171 countsByYear W28914181712022 @default.
• W2891418171 countsByYear W28914181712023 @default.
• W2891418171 crossrefType "journal-article" @default.
• W2891418171 hasAuthorship W2891418171A5001562050 @default.
• W2891418171 hasAuthorship W2891418171A5004935250 @default.
• W2891418171 hasAuthorship W2891418171A5019741373 @default.
• W2891418171 hasAuthorship W2891418171A5020955148 @default.
• W2891418171 hasAuthorship W2891418171A5028592995 @default.
• W2891418171 hasAuthorship W2891418171A5031721461 @default.
• W2891418171 hasAuthorship W2891418171A5037195922 @default.
• W2891418171 hasAuthorship W2891418171A5042503296 @default.
• W2891418171 hasAuthorship W2891418171A5043561754 @default.
• W2891418171 hasAuthorship W2891418171A5044613951 @default.
• W2891418171 hasAuthorship W2891418171A5052730435 @default.
• W2891418171 hasAuthorship W2891418171A5070005513 @default.
• W2891418171 hasAuthorship W2891418171A5070734531 @default.
• W2891418171 hasAuthorship W2891418171A5075799959 @default.
• W2891418171 hasAuthorship W2891418171A5076736008 @default.
• W2891418171 hasAuthorship W2891418171A5085317448 @default.
• W2891418171 hasConcept C121608353 @default.
• W2891418171 hasConcept C126322002 @default.
• W2891418171 hasConcept C143998085 @default.
• W2891418171 hasConcept C197934379 @default.
• W2891418171 hasConcept C2776694085 @default.
• W2891418171 hasConcept C2777701055 @default.
• W2891418171 hasConcept C2778570526 @default.
• W2891418171 hasConcept C2780057760 @default.
• W2891418171 hasConcept C2780580376 @default.
• W2891418171 hasConcept C2908647359 @default.
• W2891418171 hasConcept C31760486 @default.
• W2891418171 hasConcept C530470458 @default.
• W2891418171 hasConcept C71924100 @default.
• W2891418171 hasConcept C90924648 @default.
• W2891418171 hasConcept C99454951 @default.
• W2891418171 hasConceptScore W2891418171C121608353 @default.
• W2891418171 hasConceptScore W2891418171C126322002 @default.
• W2891418171 hasConceptScore W2891418171C143998085 @default.
• W2891418171 hasConceptScore W2891418171C197934379 @default.
• W2891418171 hasConceptScore W2891418171C2776694085 @default.
• W2891418171 hasConceptScore W2891418171C2777701055 @default.
• W2891418171 hasConceptScore W2891418171C2778570526 @default.
• W2891418171 hasConceptScore W2891418171C2780057760 @default.
• W2891418171 hasConceptScore W2891418171C2780580376 @default.
• W2891418171 hasConceptScore W2891418171C2908647359 @default.
• W2891418171 hasConceptScore W2891418171C31760486 @default.
• W2891418171 hasConceptScore W2891418171C530470458 @default.
• W2891418171 hasConceptScore W2891418171C71924100 @default.
• W2891418171 hasConceptScore W2891418171C90924648 @default.
• W2891418171 hasConceptScore W2891418171C99454951 @default.
• W2891418171 hasIssue "15_suppl" @default.
• W2891418171 hasLocation W28914181711 @default.
• W2891418171 hasOpenAccess W2891418171 @default.
• W2891418171 hasPrimaryLocation W28914181711 @default.
• W2891418171 hasRelatedWork W2140733229 @default.
• W2891418171 hasRelatedWork W2224319365 @default.
• W2891418171 hasRelatedWork W2243375749 @default.
• W2891418171 hasRelatedWork W2350328551 @default.
• W2891418171 hasRelatedWork W2406666623 @default.
• W2891418171 hasRelatedWork W2793160291 @default.
• W2891418171 hasRelatedWork W2907290230 @default.
• W2891418171 hasRelatedWork W4313236518 @default.
• W2891418171 hasRelatedWork W4313404390 @default.
• W2891418171 hasRelatedWork W4386083912 @default.
• W2891418171 hasVolume "35" @default.
• W2891418171 isParatext "false" @default.
• W2891418171 isRetracted "false" @default.
• W2891418171 magId "2891418171" @default.

• next